Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Shire sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).
Shire: 245 sponsored US clinical trials, 1 recruiting.
Shire sponsors 245 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 212 completed. 118 of these trials are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.
Top-decile sponsor footprint
Shire ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
212 of 242 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
245 total, page 3 of 5
Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
NCT01449240
Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
NCT01732263
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
NCT01620255
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
NCT01738698
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
NCT01716455
Safety Study of Lifitegrast to Treat Dry Eye
NCT01636206
Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
NCT01604941
Open Label Extension in Adults With Binge Eating Disorder (BED)
NCT01657019
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
NCT01671111
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
NCT01642212
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
NCT01611974
Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
NCT01515865
A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021
NCT01560403
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
NCT01518946
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT01552915
Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
NCT01509768
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT01552902
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT01472939
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
NCT01436175
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
NCT01386658
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
NCT01470469
Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
NCT01469637
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01436149
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
NCT01457339
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01436162
Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
NCT01442688
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
NCT01081132
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
NCT01426763
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
NCT01421498
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
NCT01147302
Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
NCT01418365
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
NCT01363908
Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine
NCT01402947
A Study To Monitor Long-Term Treatment With PF-00547659
NCT01298492
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
NCT01259726
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
NCT01343823
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
NCT01435759
Safety Study of Replagal® Therapy in Children With Fabry Disease
NCT01363492
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
NCT01291173
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
NCT01276509
A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
NCT01297309
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
NCT01268098
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01244490
Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
NCT01235338
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
NCT01130844
Effect of Teduglutide on Gastric Emptying in Healthy Subjects
NCT01209351
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
NCT01186419
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
NCT01124149
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
NCT01106430
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
NCT01096784
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 56 |
| Phase 3 | 98 |
| Phase 4 | 20 |
What is open in the Shire pipeline
1 recruiting of 245 indexed (0% open); 212 completed (87%).
Phase mix: 118 late (III/IV) vs 108 early (I/II) (balanced across stages).
Top condition: Healthy (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shire: open-pipeline peers nationwide
Peers matched on 245 registered trials and 0% open enrollment, not the therapeutic-area sidebar.
Shire sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 245 trials (± recruiting share)
- University of Cincinnati · 245 trials · 14% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
- Masonic Cancer Center, University of Minnesota · 249 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 0% open enrollment (± trial volume)
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- 10xBio · 0% recruiting · 3 trials
Related
What to do with this Shire page
245 registered trials is a research-attention snapshot, not an endorsement of Shire or any single study.
- 1 of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shire pipeline card: 245 registered trials from official public datasets.Report a data error.